source
- Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’Boehringer Ingelheim has suspended a phase 1 trial of an investigational small molecule drug while it seeks to understand a “safety event,” although the German pharma isn't shedding light on the na…Fierce Biotech · 19h ago↗ source
- Tolerance Bio secures up to $260 M for thymus‑targeting fusion protein, moves into Phase 2 trialsTolerance Bio, a Philadelphia biotech founded in October 2024, has signed a licensing agreement to acquire rights to NeoImmuneTech’s long‑acting IL‑7 fusion protein, efineptakin alfa, for up to $26…